Nexanib 200 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Sorafenib tosylate |
| Company | Jenphar bangladesh ltd |
Indications
- Hepatocellular Carcinoma
- Renal Cell Carcinoma
Pharmacology
Sorafenib is a kinase inhibitor that decreases tumor cell proliferation. It inhibits multiple intracellular and cell surface kinases thought to be involved in tumor cell signaling, angiogenesis, and apoptosis.
Dosage & Administration
The recommended daily dose of Sorafenib is 400 mg tablets taken twice daily without food. Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.
Interaction
- Carboplatin and Paclitaxel
- UGT1A1 and UGT1A9 Substrates
- Docetaxel
- Doxorubicin
- Fluorouracil
- CYP2B6 and CYP2C8 Substrates
- CYP3A4 Inducers
- CYP3A4 Inhibitors and CYP Isoform Substrates
- P-glycoprotein Substrates
- CYP Enzyme Induction
- Combination with other Antineoplastic Agents
- Neomycin
Contraindications
Sorafenib is contraindicated in patients with known severe hypersensitivity to Sorafenib or any other component of Sorafenib. In combination with carboplatin and paclitaxel, it is contraindicated in patients with squamous cell lung cancer.
Side Effects
Serious adverse reactions include cardiac ischemia, infarction, hemorrhage, hypertension, hand-foot skin reaction, rash, gastrointestinal perforation, and wound healing complications.
Pregnancy & Lactation
Sorafenib may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while on Sorafenib. It is not known whether Sorafenib is excreted in human milk.
Precautions & Warnings
- Cardiac ischemia, infarction
- Risk of Hemorrhage
- Risk of Hypertension
- Risk of Dermatologic Toxicities
- Risk of Gastrointestinal Perforation
- Warfarin Co-Administration
- Wound Healing Complications
- Use of Nexanib in combination with Carboplatin and Paclitaxel in Non-small Cell Lung Cancer
- Interactions with UGT1A1 Substrates
- Interaction with Docetaxel & Doxorubicin
- Hepatic Impairment
- Neomycin
Use in Special Populations
- Pediatric Use
- Geriatric Use
- Renal impairment
- Hepatic impairment
Overdose Effects
There is no specific treatment for Sorafenib overdose. The highest dose studied clinically is 800 mg twice daily, with observed adverse reactions primarily being diarrhea and dermatologic.
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
Store at room temperature below 30°C. Do not remove desiccant. Dispense in original bottle.